Potassium Hydroxide
drugOn this page
Also known as Caustic potashCaustic-potashE-525INS NO.525INS-525Kali causticumPotassium hydroxide solution
Summary
Potassium Hydroxide (CHEMBL2103983) is an approved small molecule; indicated across 1 condition including molluscum contagiosum.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 1 condition
- Clinical trials: 1
- Chemistry: 56.106 Da · HKO
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2103983 |
| Name | Potassium Hydroxide |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | yes |
| PubChem CID | 14797 |
| ChEBI | CHEBI:32035 |
| Molecular formula | HKO |
| Molecular weight | 56.106 |
| InChIKey | KWYUFKZDYYNOTN-UHFFFAOYSA-M |
SMILES: [OH-].[K+]
IUPAC name: potassium hydroxide
Also known as: Caustic potash, Caustic-potash, E-525, INS NO.525, INS-525, Kali causticum, Potassium hydroxide, Potassium hydroxide solution, POTASSIUM HYDROXIDE
Patent coverage: 439,115 distinct patent families (1,046,612 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| molluscum contagiosum | 2 | MONDO:0005855 | EFO:0007375 |
Clinical trials
Total trials: 1.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05634460 | PHASE1 | COMPLETED | Comparison of 5% Potassium Hydroxide With 10% Potassium Hydroxide Solution in Treatment of Molluscum Contagiosum |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.